顺铂植入剂经皮肝植入治疗肝癌的药动学研究

刘华顶 王世亮 叶红杨 许健健 储成顶 宣凤琴

中国药学杂志 ›› 2010, Vol. 45 ›› Issue (22) : 1753-1757.

PDF(780 KB)
PDF(780 KB)
中国药学杂志 ›› 2010, Vol. 45 ›› Issue (22) : 1753-1757.
论 著

顺铂植入剂经皮肝植入治疗肝癌的药动学研究

  • 刘华顶1,4,王世亮2,3,叶红杨2,许健健2,储成顶2,4*,宣凤琴3
作者信息 +

Pharmacokinetics of Cisplatin Implants with Percutaneous Liver Insertion in the Liver Cancer Therapy

  • LIU Hua-ding1,4,WANG Shi-liang2,3,YE Hong-yang2,XU Jian-jian2,CHU Cheng-ding2,4*,XUAN Feng-qin3
Author information +
文章历史 +

摘要

目的 探讨顺铂植入剂在肝癌患者肿瘤部位植入后的药动学规律。 方法 B超引导下,用穿刺器械在肝癌患者瘤内多点穿刺植药;采集静脉血,石墨炉原子吸收法测定,测定结果进行加权处理、药动学模型拟合。 结果 顺铂植入剂在体内的过程为一室缓释模型,药动学方程是:ρt=A1 e-Ke t+A2e-Ka t+A3e-Kr t ,血药达峰时间及峰浓度分别为110 h及0.35 mg·L-1,吸收、消除半衰期分别为2及300 h。 结论 此种给药方法的全身血循环药动学特点和参数,可为临床合理应用顺铂植入剂进行肝癌瘤内局部植入的间质化疗提供参考依据。

Abstract

OBJECTIVE To demonstrate pharmacokinetic properties of cisplatin implants in patients receiving percutaneous liver implantation for treating hepatocellular carcinoma. METHODS Under ultrasound-guided,multiple needle punctures were made and the insertion of cisplantin implants performed in the tumor. Venous blood samples with different intervals were collected accordingly. The samples were determined with graphite furnace atomic absorption spectrometry,and the obtained data were processed and described with the pharmacokinetic model. RESULTS The in vivo course of cisplatin implants was expressed as the one compartment model. The main pharmacokinetic parameters were as follows: ρt =A1e-Ke t+A2e-Ka t+A3 e-Kr t. The peak time tmax and corresponding peak concentration ρmax of cisplatin were 110 h and 0.35 mg·L-1 ,respectively. The absorption half-life was 2 h,and the elimination half-life was 300 h. CONCLUSION This study results provide pharmacokinetic profile for the percutaneous liver insertion of cisplatin implants clinically for the interstitial chemotherapy.

关键词

顺铂 / 植入剂 / 原发性肝癌 / 经皮肝植入 / 石墨炉原子吸收法 / 药动学

Key words

cisplatin / implants / hepatocellular carcinoma / percutaneous liver insertion / GF-AAS / pharmacokinetics

引用本文

导出引用
刘华顶 王世亮 叶红杨 许健健 储成顶 宣凤琴. 顺铂植入剂经皮肝植入治疗肝癌的药动学研究[J]. 中国药学杂志, 2010, 45(22): 1753-1757
LIU Hu-ding;WNG Shi-ling;YE Hong-yng;XU Jin-jin;CHU Cheng-ding;XUN Feng-qin. Pharmacokinetics of Cisplatin Implants with Percutaneous Liver Insertion in the Liver Cancer Therapy[J]. Chinese Pharmaceutical Journal, 2010, 45(22): 1753-1757

参考文献


[1] BARABAS K,MILNER R,LURIE D,et al. Cisplatin: a review of toxicities and therapeutic applications[J]. Vet Comp Oncol,2008,6(1): 1-18.
[2] YAPP D T,LLOYD D K,ZHU J. Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or ip injection in tumor-bearing mice[J]. Anticancer Drugs,1998,9(9): 791-796.
[3] GE Y Q,ZHANG Y Q,LU G C,et al. Simultaneous determination of cisplatin and etoposide in plasma and tissue by HPLC[J]. Chin J Pharm Anal(药物分析杂志),2003,23(2): 87-90.
[4] GRYPARIS E C,HATZIAPOSTOLOU M,PAPADIMITRIOU E. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells[J]. Eur J Pharm Biopharm,2007,67(1): 1-8.
[5] SUN Y,SHI Y K. Clinical Manual for Internal Medicine(内科医学临床手册)[M]. 5th ed. Beijing: People′s Medical Publishing House, 2008: 10-11.
[6] FENG M,AN H J. Interstitial chemotherapy for liver,gall-bladder and pancreatic carcinomas. In Li Y,New technique of the micro-invasive treatments against the liver,gall-bladder and pancreatic carcinomas(肝癌、胆囊和胰腺癌的微创治疗新技术)[M]. Beijing: Beijing Science and Technology Press, 2009:211-241.
[7] KIM J H ,KIM Y S ,PARK K. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice[J].J Controlled Release, 2008,127: 41-49.
[8] BIASINO J,DOM NGUEZ J R,ALVARADO J. Hydrogen peroxide in basic media for whole blood sample dissolution for determination of its lead content by electrothermal atomization atomic absorption spectrometry[J]. Talanta, 2007,73(5): 962-964.
[9] RAGHAVAN R,MULLIGAN J A. Low-level (PPB) determination of cisplatin in cleaning validation (rinse water) samples. I. An atomic absorption spectrophotometric method[J]. Drug Dev Ind Pharm,2000,26(4): 423-428.
[10] IUPAC. Nomenclature,symbols, units and their usage in spectrochemical analysis - III. Analytical flame spectroscopy and associated non-flame procedures[J]. Pure Appl Chem,1976,45(2): 106-122.
[11] Ch.P(2005). vol Ⅱ(中国药典2005年版.二部)[S]. 2005: 172-173.
[12] Ch.P(2005). vol Ⅱ[S]. suppl, 2005: 173-176.
[13] CHU C D,CHENG W,WANG S L,et al. The pharmacokinetic model for a target therapeutic system of sustained-release implants[J]. Chin J New Drugs(中国新药杂志),2004,13(7): 613-616.
[14] LUO J H,YANG Y B,LI J C. Chronopharmacokinetics of cisplatin in rabbits[J]. Chin Pharmacol Bull(中国药理学通报),1999,15(4): 363-365.
[15] WANG S L,WANG J,YIN Q S,et al. Behavior of cisplatin implants in protein denaturant acetic acid[J]. J China Pharm Univ(中国药科大学学报),2008,39(3): 214-217.
PDF(780 KB)

68

Accesses

0

Citation

Detail

段落导航
相关文章

/